Cofactor Genomics announced the publication of results from the PREDAPT clinical trial (NCT04510129) in the Journal for ImmunoTherapy of Cancer, showcasing the clinical validity and utility of OncoPrism-HNSCC in predicting response to immune checkpoint inhibitors (ICI) for head and neck squamous cell carcinoma (HNSCC) patients. The multicenter study involved 17 healthcare systems and demonstrated that OncoPrism-HNSCC significantly predicted disease control and progression-free survival in patients treated with ICI, either as a single agent or in combination with chemotherapy.
Enhanced Specificity and Sensitivity
The study reported a 300% improvement in specificity over PD-L1 CPS and a 400% improvement in sensitivity over Tumor Mutational Burden (TMB) in predicting patient benefit from ICI. These improvements address the limitations of PD-L1 and TMB, which have been associated with over-treatment and poorer outcomes for HNSCC patients.
Clinical Impact and Expert Opinion
Dr. Douglas Adkins, MD, head and neck oncologist and Professor of Medicine at Washington University School of Medicine, stated, "The OncoPrism assay provides a new and important tool to help clinicians decide about treatment options for their patients with recurrent or metastatic head and neck cancer." This highlights the potential of OncoPrism-HNSCC to bridge the precision medicine gap by providing clinicians with the data needed to make better treatment decisions.
RNA-Based Assay and Health Expression Models
OncoPrism-HNSCC leverages Cofactor's Health Expression Models, which use RNA expression paired with machine learning to directly measure the body’s immune response to cancer. According to Dr. Eric Duncavage, MD, Cofactor Genomics’ Medical Director, these models represent an emerging category of diagnostic technologies that can be used to better predict immunotherapy treatment response in cancer patients, enabling precision medicine where other technologies lack sufficient diagnostic specificity.
About OncoPrism-HNSCC
OncoPrism-HNSCC is a CAP/CLIA-validated and Medicare-approved test designed to predict benefit from immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). It is intended to provide clinicians with additional information to guide treatment decisions and improve patient outcomes.
